Rare Discordance Between DPYD HapB3 Markers Challenges Cancer Drug Phenotype Predictions
A study of 3,276 patients shows that rare biological discordance and technical misclassification between DPYD HapB3 variants can compromise pharmacogenetic ...
A study of 3,276 patients shows that rare biological discordance and technical misclassification between DPYD HapB3 variants can compromise pharmacogenetic ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.